China Universal Asset Management Company’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-41
Closed -$815 – 481
2023
Q3
$815 Buy
41
+20
+95% +$862 ﹤0.01% 443
2023
Q2
$1.61K Sell
21
-1
-5% -$81 ﹤0.01% 437
2023
Q1
$2.05K Buy
22
+6
+38% +$571 ﹤0.01% 431
2022
Q4
$1.58K Buy
16
+3
+23% +$435 ﹤0.01% 384
2022
Q3
$3K Buy
+13
New +$3.78K ﹤0.01% 337

Other funds holding TCRT

China Universal Asset Management Company's TCRT Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 41 shares — an estimated $815 sold.

China Universal Asset Management Company first reported a position in TCRT in Q3 2022 and held it in 5 quarters. The position peaked at $3K in Q3 2022. 83 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

  • China Universal Asset Management Company reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • China Universal Asset Management Company sold 41 Alaunos Therapeutics shares in Q4 2023, an estimated $815.
  • China Universal Asset Management Company first reported a position in Alaunos Therapeutics in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Alaunos Therapeutics position peaked at $3K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.